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Lymphoblastic lymphoma (LBL) is a rare disease accounting 
for approximately 8% of all lymphoid malignancies. Bone 
marrow involvement <25% is the formal cut-off which 
distinguishes LBL from acute lymphoblastic leukemia 
(ALL) but the World Health Organization encodes both 
LBL and ALL as one disease. In ALL there are well-
defined parameters, i.e., cytogenetic aberrations, that lead 
the clinician to correctly stratify patients’ risk: these are not 
well studied in LBL. 
We report here a case of a 31-year-old male with 
unprecedented medical history whose first access to the 
hospital was in August 2015 complaining about constant 
back pain not responsive to pain meds, night sweats and 
fever. 
Biochemistry work-up showed mild normocytic anemia, 
normal WBC and platelets counts as well as LDH and B2 
microglobulin and negative HIV, HBV and HCV serology.
A total body CT scan was performed and showed a 
paravertebral mass (64×80 mm) between 4° and 6° rib with 
osteolytic aspect and involvement of D4-D5 intervertebral 
foramen. CT was followed by PET-scan which confirmed 
the presence of the mass with high metabolic activity in the 
aforementioned locations.
A biopsy of the mass was done and came back diagnostic 
of B-LBL. Contemporarily the bone marrow was 
analyzed: the cytofluorimetric analysis didn’t detect any 
B-lymphoblasts but RT-PCR showed low molecular level 
BCR-ABL p190 positivity (ratio, 0.4718%). At this point 
we extracted RNA from the mass sample, and we performed 
RQ-PCR for BCR-ABL/ABL with a confirmed positive 
level of 69.76%. BCR-ABL positivity was also confirmed on 
peripheral blood with a BCR-ABL/ABL ratio of 0.41%.
Notably, the FISH analysis on bone marrow for 
Philadelphia positive cells was negative, whereas FISH 
analysis on the biopsy specimen was positive for BCR/ABL 
fusion in 81% of the cells.
The patient initiated treatment with steroids 7 days 
prior to starting a daily dose of imatinib 800 mg which was 
rapidly switched to dasatinib 140 mg/day. At the same time 
a diagnostic-therapeutic lumbar puncture was performed 
with the injection of intrathecal Methotrexate (MTX) and 
cytarabine: the cerebrospinal fluid (CSF) analysis came back 
clear. Steroids therapy was continued for 3 weeks after the 
introduction of tyrosin-kinase inhibitor (TKI) and then 
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rapidly tapered until complete suspension in 10 days. 
After 1 month of TKIs, first imatinib then dasatinib, a 
CT scan with contrast was repeated showing consistent 
reduction of the mass size. One course of zoledronic acid 
was administered due to the osteolytic aspects of the mass.
Other three lumbar puncture were performed beyond 
the one at diagnosis: they were all negative for disease 
infiltration and prophylactic cytarabine, methotrexate and 
dexamethasone were injected in the CSF. 
Successive molecular evaluations on peripheral blood 
and bone marrow were conducted monthly with a slow 
clearance of BCR-ABL (see Figure 1).
In December 2015, just before transplantation, patient 
was treated with involved field radiotherapy (12 Gy total) 
on the residual paravertebral lesion.
The patient then underwent allogeneic bone marrow 
transplant from matched sibling donor in January 
2016 using the standard ALL Cyclophosphamide-
TBI conditioning regimen. PET scan made just before 
transplantation showed complete disappearance of cancer, 
although a low level of BCR-ABL positivity was still slightly 
detectable. The procedure was well tolerated; GVHD 
prophylaxis included methotrexate, ATG and CSA. After 
transplant the patient suffered from grade II gut GVHD 
which was managed with high dose steroids at first and then 
tapered until complete discontinuation. 
According to the centre policy and the pre-transplant 
BCR/ABL positivity, on day +45 after transplant the patient 
was started on dasatinib 50 mg/day, then shifted after 
1 month to imatinib 300 mg/day due to poor hematological 
tolerance. Imatinib was increased at the standard dose 
of 400 mg/day in July 2016 as soon as the hematological 
tolerance improved. 
After transplant evaluation of BCR/ABL and chimerism 
were performed monthly and the persistent molecular 
positivity led to shift therapy from imatinib to dasatinib in 
August 2017. Since dasatinib introduction, which was well 
tolerated with no side effects at all, BCR-ABL/ABL level 
dropped to 0% and stayed molecular negative in every 
reverse transcription polymerase chain reaction (RT-PCR) 
evaluation. 
Thirty months have passed since transplantation and 
the patient continues hematological follow-up, he’s back to 
work without complaining about any side effects neither 
from transplant nor dasatinib maintenance therapy.
Discussion
Philadelphia positive LBL is a rare entity which represents a 
real challenge for hematologists: there’s the chance that this 
entity is often underdiagnosed especially in departments 
where qualitative PCR for BCR/ABL rearrangement is 
not routinely done; once doctors are able to catch the 
diagnosis the role of usual ALL negative risk factors such 
as hypodiploidy and/or other abnormal karyotype are not 
well defined (1) and that can lead to a real dilemma about 
induction therapy and consolidation.
Literature about Ph positive lymphoblastic lymphoma 
is very scarce: there’s a case-report about a 27 years old 
man with primary testicular Ph-positive B LBL, for which 
fluorescent in-situ hybridization (FISH) for the Philadelphia 
chromosome was performed only at relapse when the 
Figure 1 BCR-ABL/ABL IS level from diagnosis to last follow-up.
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patient already had suffered from complications of intensive 
chemo regimen and showed central nervous system (CNS) 
progression which led him to death (2). The case presented 
here is very similar to another patient with lymphoblastic 
lymphoma diagnosed on a 77 years old man whose story 
started with back pain leading to the detection of a Ph 
positive lymphoblastic mass situated on L5 with a secondary 
localization on the testicles: the man was treated with hyper-
CVAD backbone plus dasatinib, then imatinib and finally 
nilotinib; he relapsed and died just before starting ponatinib 
plus blinatumomab combination as salvage therapy 4 years 
after the diagnosis (3).
Treatment of LBL, either B- or T-cell is based today 
on ALL protocols which led to an improvement of long-
term outcome (4). No recommendation are made for 
Ph positive lymphoblastic lymphoma because of lack of 
experience on a large scale; to our knowledge this is the 
first case report about a Philadelphia positive LBL patient 
who is not only alive but also in a good clinical status and 
complete remission 3 years from diagnosis using a chemo-
free regimen in induction (as in the Italian GIMEMA 
protocols fashion about Ph positive ALL), allo-transplant as 
consolidation from sibling donor and 2GTKI maintenance. 
This case-report has also the aim to underline the 
importance of testing for BCR-ABL rearrangement all the 
masses that are compatible with B-cell LBL as a positivity 
could dramatically change the treatment of the patient.
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